BR112019012972B1 - Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos - Google Patents

Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos Download PDF

Info

Publication number
BR112019012972B1
BR112019012972B1 BR112019012972-3A BR112019012972A BR112019012972B1 BR 112019012972 B1 BR112019012972 B1 BR 112019012972B1 BR 112019012972 A BR112019012972 A BR 112019012972A BR 112019012972 B1 BR112019012972 B1 BR 112019012972B1
Authority
BR
Brazil
Prior art keywords
compound
fact
solvent
reaction mixture
formula
Prior art date
Application number
BR112019012972-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112019012972A2 (pt
Inventor
Ana Maria Garcia Collazo
Wolter ten Hoeve
Johannes Nicolaas Koek
Johannes B.M. Rewinkel
Sander DE WILDE
Original Assignee
Minoryx Therapeutics S.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S.L filed Critical Minoryx Therapeutics S.L
Publication of BR112019012972A2 publication Critical patent/BR112019012972A2/pt
Publication of BR112019012972B1 publication Critical patent/BR112019012972B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127Preparation from compounds containing pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112019012972-3A 2016-12-23 2017-12-22 Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos BR112019012972B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
EP16382648.0 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Publications (2)

Publication Number Publication Date
BR112019012972A2 BR112019012972A2 (pt) 2019-12-31
BR112019012972B1 true BR112019012972B1 (pt) 2023-04-18

Family

ID=57799523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012972-3A BR112019012972B1 (pt) 2016-12-23 2017-12-22 Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos

Country Status (19)

Country Link
US (2) US11124505B2 (https=)
EP (1) EP3559010B1 (https=)
JP (2) JP7294661B2 (https=)
KR (1) KR102609373B1 (https=)
CN (1) CN110198945B (https=)
BR (1) BR112019012972B1 (https=)
CA (1) CA3046744A1 (https=)
CY (1) CY1125531T1 (https=)
DK (1) DK3559010T3 (https=)
ES (1) ES2926580T3 (https=)
HR (1) HRP20221067T1 (https=)
HU (1) HUE059604T2 (https=)
IL (1) IL267557B (https=)
LT (1) LT3559010T (https=)
MX (1) MX379709B (https=)
PL (1) PL3559010T3 (https=)
PT (1) PT3559010T (https=)
SI (1) SI3559010T1 (https=)
WO (1) WO2018116281A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
CN112823004A (zh) 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途
EP3801515B1 (en) 2018-06-06 2025-04-09 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
CN112512524A (zh) 2018-06-06 2021-03-16 米尼奥尔克斯治疗有限公司 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231886T2 (de) * 1991-04-11 2002-03-28 Pharmacia & Upjohn Co., Kalamazoo Thiazolidindionderivate, herstellung und anwendung
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
CA2594666A1 (en) 2005-02-16 2006-08-24 Micromet Ag Use of activated polymers for separation of protein and polypeptide multimers
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JPWO2008136428A1 (ja) * 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2855489B1 (en) * 2012-04-26 2017-01-04 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EA202091120A3 (ru) 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma

Also Published As

Publication number Publication date
US20190389852A1 (en) 2019-12-26
CN110198945A (zh) 2019-09-03
HRP20221067T1 (hr) 2022-11-25
IL267557B (en) 2021-10-31
EP3559010A1 (en) 2019-10-30
IL267557A (en) 2019-08-29
PL3559010T3 (pl) 2022-11-21
SI3559010T1 (sl) 2022-10-28
PT3559010T (pt) 2022-09-01
CY1125531T1 (el) 2026-02-25
MX379709B (es) 2025-03-11
HUE059604T2 (hu) 2022-11-28
ES2926580T3 (es) 2022-10-27
KR20190100300A (ko) 2019-08-28
BR112019012972A2 (pt) 2019-12-31
US20220204496A1 (en) 2022-06-30
DK3559010T3 (da) 2022-08-15
US11731963B2 (en) 2023-08-22
JP2023052918A (ja) 2023-04-12
JP2020502228A (ja) 2020-01-23
CN110198945B (zh) 2023-06-27
LT3559010T (lt) 2022-10-10
EP3559010B1 (en) 2022-06-08
CA3046744A1 (en) 2018-06-28
JP7294661B2 (ja) 2023-06-20
KR102609373B1 (ko) 2023-12-01
MX2019007327A (es) 2019-09-02
WO2018116281A1 (en) 2018-06-28
US11124505B2 (en) 2021-09-21

Similar Documents

Publication Publication Date Title
BR112019012972B1 (pt) Compostos e processos para a preparação de metabólitos da pioglitazona, bem como intermediários dos mesmos
EP3112340A1 (en) Method for producing 4-borono-l-phenylalanine having 18f atom introduced thereinto, and precursor of 4-borono-l-phenylalanine having 18f atom introduced thereinto
US20120004417A1 (en) Fluorination of aromatic ring systems
US9302990B2 (en) Fluorination of aromatic ring systems
US20220249710A1 (en) Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
WO2009138763A1 (en) Formation of 18f and 19f fluoroarenes bearing reactive functionalities
JP2015523985A (ja) ジアリールヨードニウム塩を製造するための方法及び反応剤
US9434740B2 (en) Taxane compounds, compositions and methods
EP3594200B1 (en) Radioactive fluorine-labeled precursor compound, and method for producing radioactive fluorine-labeled compound using same
CN109415383A (zh) 制备艾日布林的方法及其中间体
CN116457357A (zh) 稠合的三并环衍生物及其在药学上的应用
HK40014767B (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
HK40014767A (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
ES2714628B2 (es) Compuestos derivados de la vitamina D
KR101925650B1 (ko) 결정화에 의한 전구체 화합물의 정제
HK40013289B (zh) 用於制备噻唑烷二酮化合物及其盐的方法
HK40013289A (en) Process for preparing thiazolidinedione compounds and salts thereof
JP2007031647A (ja) 固相合成を利用した超短半減期核種を含む化合物の製造方法およびそれに用いる化合物
HK1197053A1 (zh) 新型谷氨酸酯衍生物的前体
CN104530111A (zh) 化合物三甲基(3-(三甲基硅基)苄氧基)硅烷及其制备方法和应用
HK1197053B (en) Novel precursors of glutamate derivatives

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2017, OBSERVADAS AS CONDICOES LEGAIS